

Hyeoung-Joon Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2872949/publications.pdf>

Version: 2024-02-01

141
papers

2,139
citations

236925

25
h-index

330143

37
g-index

142
all docs

142
docs citations

142
times ranked

3636
citing authors

#	ARTICLE	IF	CITATIONS
1	Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. <i>Haematologica</i> , 2016, 101, 717-723.	3.5	129
2	Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. <i>Blood</i> , 2018, 132, 1604-1613.	1.4	84
3	Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 287-294.	2.5	77
4	Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2013, 92, 471-479.	1.8	69
5	Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2004, 19, 66-70.	1.3	68
6	Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. <i>Experimental Hematology</i> , 2017, 46, 48-55.	0.4	53
7	Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. <i>Oncotarget</i> , 2017, 8, 27252-27262.	1.8	52
8	Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 1-5.	4.1	51
9	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
10	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. <i>Oncotarget</i> , 2017, 8, 41538-41548.	1.8	39
11	Na ⁺ -ve CD8 ⁺ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	3.3	36
12	CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2003, 73, 149-153.	4.1	35
13	¹⁸ F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 107-115.	6.4	34
14	Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	2.2	33
15	Immunotherapy for the treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 87-93.	4.4	33
16	Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model. <i>Frontiers in Immunology</i> , 2018, 9, 1798.	4.8	32
17	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
18	Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Array-Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype. <i>Journal of Clinical Oncology</i> , 2011, 29, 4702-4708.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. <i>European Journal of Haematology</i> , 2015, 95, 442-448.	2.2	30
20	Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 341-347.	1.3	30
21	The <i>IFNG</i> (IFN- γ) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5339-5350.	7.0	29
22	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
23	Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. <i>Chonnam Medical Journal</i> , 2015, 51, 1.	0.9	27
24	Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. <i>Leukemia Research</i> , 2017, 59, 142-148.	0.8	27
25	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 212.	1.7	27
26	Hemolytic Anemia as a Sequela of Arsenic Intoxication Following Long-Term Ingestion of Traditional Chinese Medicine. <i>Journal of Korean Medical Science</i> , 2004, 19, 127.	2.5	26
27	Association of <i>GSTT1</i> polymorphism with acute myeloid leukemia risk is dependent on smoking status. <i>Leukemia and Lymphoma</i> , 2012, 53, 681-687.	1.3	26
28	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
29	<i>OCT-1</i> , <i>ABCB1</i> , and <i>ABCG2</i> Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. <i>Chonnam Medical Journal</i> , 2014, 50, 102.	0.9	25
30	Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes <i>in vitro</i> . <i>Experimental Hematology</i> , 2014, 42, 274-281.	0.4	25
31	Incidences and Prognostic Impact of <i>c-KIT</i> , <i>WT1</i> , <i>CEBPA</i> , and <i>CBL</i> Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. <i>Annals of Laboratory Medicine</i> , 2015, 35, 288-297.	2.5	25
32	Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. <i>The Korean Journal of Hematology</i> , 2010, 45, 36.	0.7	24
33	Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. <i>Blood Research</i> , 2015, 50, 19.	1.3	24
34	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
35	Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. <i>Oncotarget</i> , 2017, 8, 46047-46056.	1.8	24
36	Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma. <i>American Journal of Hematology</i> , 2007, 82, 798-801.	4.1	23

#	ARTICLE	IF	CITATIONS
37	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. <i>Blood Research</i> , 2017, 52, 293.	1.3	23
38	<i>FLT3</i> mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. <i>Blood Research</i> , 2022, 57, S32-S36.	1.3	22
39	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 31-45.	4.2	20
40	Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. <i>Annals of Hematology</i> , 2013, 92, 459-469.	1.8	19
41	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
42	Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. <i>Leukemia Research</i> , 2001, 25, 1067-1073.	0.8	18
43	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6703-6716.	4.1	18
44	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
45	PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males. <i>BMC Medical Genetics</i> , 2010, 11, 38.	2.1	17
46	The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	17
47	Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response4.5 (CMR4.5). <i>Blood</i> , 2011, 118, 2763-2763.	1.4	17
48	Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. <i>Leukemia Research</i> , 2008, 32, 993-995.	0.8	16
49	Selective transfection with osmotically active sorbitol modified PEI nanoparticles for enhanced anti-cancer gene therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 119, 126-136.	5.0	16
50	<i>In vitro</i> induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2012, 44, 60.	7.7	15
51	Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 389-394.	0.4	15
52	Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca ²⁺ transport ATPase 2 regulation. <i>Cytotherapy</i> , 2015, 17, 1421-1433.	0.7	15
53	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
54	Sarcoplasmic reticulum Ca ²⁺ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. <i>Experimental and Molecular Medicine</i> , 2016, 48, e253-e253.	7.7	15

#	ARTICLE	IF	CITATIONS
55	Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 821-825.	4.1	14
56	Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116.	1.6	14
57	Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study. <i>Annals of Hematology</i> , 2016, 95, 1223-1232.	1.8	14
58	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	7.2	14
59	Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 613-625.	4.2	14
60	Chemical Modification of Santonin into a Diacetoxy Acetal Form Confers the Ability to Induce Differentiation of Human Promyelocytic Leukemia Cells via the Down-regulation of NF- κ B DNA Binding Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 13117-13125.	3.4	13
61	A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2015, 102, 401-412.	1.6	13
62	Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 44-55.	2.8	12
63	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
64	Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study). <i>Blood</i> , 2011, 118, 2765-2765.	1.4	12
65	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
66	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 100-107.	5.2	12
67	5-diphenylacetamido-indirubin-3-oxime as a novel mitochondria-targeting agent with anti-leukemic activities. <i>Molecular Carcinogenesis</i> , 2016, 55, 611-621.	2.7	11
68	Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e391-e399.	0.4	11
69	Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 59.	2.6	11
70	Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2224-2233.	1.3	10
71	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
72	FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF- κ B signaling activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 82.	8.6	10

#	ARTICLE	IF	CITATIONS
73	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 82.	4.4	9
74	Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61.	1.8	9
75	<scp> </scp>-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH) ₂ D ₃ -induced myeloid differentiation in acute myeloid leukemia cells. <i>International Journal of Cancer</i> , 2017, 140, 2364-2374.	5.1	9
76	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. <i>Annals of Hematology</i> , 2019, 98, 1135-1147.	1.8	9
77	Cellular immunotherapy in multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 954-965.	1.7	9
78	Clinical Significance of CD56 Expression in Patients with Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 1897-1899.	1.3	8
79	Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 822-824.	4.1	8
80	A genome-wide single nucleotide polymorphism array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 961-968.	4.1	8
81	Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2012, 96, 327-333.	1.6	8
82	Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	8
83	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	2.5	8
84	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <i>Leukemia Research</i> , 2017, 60, 135-144.	0.8	8
85	Analysis of gene profiles involved in the enhancement of all-trans retinoic acid-induced HL-60 cell differentiation by sesquiterpene lactones identifies asparagine synthetase as a novel target for differentiation-inducing therapy. <i>International Journal of Oncology</i> , 2014, 44, 970-976.	3.3	7
86	Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. <i>British Journal of Haematology</i> , 2013, 163, 62-71.	2.5	6
87	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2016, 11, e0166245.	2.5	6
88	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). <i>BMC Cancer</i> , 2018, 18, 729.	2.6	6
89	Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. <i>Leukemia Research</i> , 2018, 70, 100-105.	0.8	6
90	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6

#	ARTICLE	IF	CITATIONS
91	A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1599-1601.	10.5	6
92	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
93	Secondary Myeloid/Natural Killer Cell Acute Leukemia Following T-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 41, 457-460.	1.3	5
94	Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2020, 99, 83-91.	1.8	5
95	Ruptured <i>Klebsiella pneumoniae</i> liver abscess after high-dose cyclophosphamide for severe aplastic anemia. <i>American Journal of Hematology</i> , 2000, 64, 218-220.	4.1	4
96	Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. <i>Oncology Reports</i> , 2015, 34, 488-494.	2.6	4
97	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4
98	Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry. <i>PLoS ONE</i> , 2021, 16, e0251011.	2.5	4
99	Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. <i>Journal of Hematology and Oncology</i> , 2022, 15, 56.	17.0	4
100	Aberrant proteomic expression of NSRP70 and its clinical implications and connection to the transcriptional level in adult acute leukemia. <i>Leukemia Research</i> , 2014, 38, 1252-1259.	0.8	3
101	Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 955-965.	1.8	3
102	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
103	Adrenal insufficiency in hospitalized patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 501-503.	1.3	2
104	Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS). <i>Blood</i> , 2019, 134, 1643-1643.	1.4	2
105	A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma. <i>Blood</i> , 2019, 134, 1819-1819.	1.4	2
106	Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Korean Medical Science</i> , 2022, 37, e2.	2.5	2
107	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.9	1
108	Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment. <i>Blood Research</i> , 2015, 50, 167.	1.3	1

#	ARTICLE	IF	CITATIONS
109	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. <i>Experimental Hematology</i> , 2019, 75, 26-30.	0.4	1
110	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e367-e373.	0.4	1
111	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
112	Comparison of the Peripheral Blood Stem Cell Mobilization and Harvest after Each Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia in First Complete Remission Who Underwent Autologous Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5495-5495.	1.4	1
113	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
114	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in Mouse Multiple Myeloma Model. <i>Blood</i> , 2012, 120, 5010-5010.	1.4	1
115	Retrospective Case Series Study of Hypomethylating Therapy in IPSS Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1992-1992.	1.4	1
116	Clinical Correlation of CD4+CD25+ Regulatory T Cells in Early Immune Reconstitution after Myeloablative Allogeneic Stem Cell Transplantation. <i>Chonnam Medical Journal</i> , 2009, 45, 154.	0.1	0
117	Clinical features and outcomes of hypocellular acute myeloid leukemia in adults. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT₀ /Overl</i>	1.0	0
118	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
119	Biological Significance and Profile of Length Heteroplasmy in the Hypervariable Segments of the Human Mitochondrial DNA Control Regions from Blood Cells.. <i>Blood</i> , 2004, 104, 3815-3815.	1.4	0
120	Clinical Significance of FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia Who Underwent Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004, 104, 4419-4419.	1.4	0
121	Interleukin-10 (IL-10) Promoter Gene Polymorphism (âˆ’819*C) Associated with Poor Clinical Outcome in DLBCL Patients Treated with R (Rituximab)-CHOP Regimen as a First Line.. <i>Blood</i> , 2005, 106, 1923-1923.	1.4	0
122	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3288-3288.	1.4	0
123	Two Single Nucleotide Polymorphisms of the ETS2 Transcriptional Factor Gene Predispose Individuals to High-Risk Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 2729-2729.	1.4	0
124	Methylenetetrahydrofolate Reductase and Methionine Synthase Polymorphism and Risk of Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2005, 106, 4691-4691.	1.4	0
125	The Feasibility Study for Using FLT3/ITD as a Marker of the Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) by Serial Analysis in Diagnosis, Remission and Relapse.. <i>Blood</i> , 2005, 106, 4515-4515.	1.4	0
126	Clinical Usefulness and Therapeutic Plan with Interim PET/CT Analysis in Malignant Lymphoma.. <i>Blood</i> , 2006, 108, 2403-2403.	1.4	0

#	ARTICLE	IF	CITATIONS
127	The Impact of Alemtuzumab as a Component of Conditioning Regimens on Transplantation Outcomes in a Setting of CMV-Seropositive Recipient and Donor.. Blood, 2006, 108, 5270-5270.	1.4	0
128	The Generation of Potent Dendritic Cells Can Be Modulated by Interaction between Immature Dendritic Cells and Invariant NK Cells with the Presence of Stimulatory Cytokines and TLR Agonist.. Blood, 2007, 110, 4896-4896.	1.4	0
129	Association Between Genetic Polymorphism in DNA Repair Genes and Acute Myeloid Leukemia.. Blood, 2009, 114, 4131-4131.	1.4	0
130	The Lymphoid Chemokine CCL21 Enhances the Migration- and CTL-Inducing Functions of Dendritic Cells. Blood, 2011, 118, 1127-1127.	1.4	0
131	NPM1, IDH1/2 and DNAM1 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation.. Blood, 2012, 120, 2534-2534.	1.4	0
132	Incidence and Clinical Features of Core Binding Factor Acute Myeloid Leukemia: A Collaborative Study of the Japan Adult Leukemia Study Group and the Korean Society of Hematology.. Blood, 2012, 120, 2584-2584.	1.4	0
133	An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. Blood, 2014, 124, 1052-1052.	1.4	0
134	Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements. Blood, 2015, 126, 1446-1446.	1.4	0
135	In the Novel Agents Era, Is the International Staging System Still Has the Prognostic Value in Patients with Renal Impairment?. Blood, 2015, 126, 5313-5313.	1.4	0
136	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. Blood, 2016, 128, 2876-2876.	1.4	0
137	18f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 4483-4483.	1.4	0
138	Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model. Blood, 2018, 132, 3194-3194.	1.4	0
139	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. Blood, 2018, 132, 3876-3876.	1.4	0
140	Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. Blood, 2021, 138, 3450-3450.	1.4	0
141	Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease. Blood, 2021, 138, 2889-2889.	1.4	0